This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
by Zacks Equity Research
Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Worried About Dow's Massive Crash? ETF & Stocks to Play
by Sanghamitra Saha
Rising fears of a second wave of lockdown globally sent Wall Street crashing on Wednesday with the Dow Jones being one of the worst hurt.
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
Wall Street Opens Green on Strong Economic Data
by Zacks Equity Research
Wall Street Opens Green on Strong Economic Data.
Markets Buoy on Durable Goods, Q3 Earnings: MRK, CAT, MMM, AMD
by Mark Vickery
Markets are up in early trading today, even though a congressional stimulus package looks kaput.
Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance
by Zacks Equity Research
Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.
Merck (MRK) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 20.83% and 2.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Big Techs to Report Earnings Results This Week
by Zacks Equity Research
Big Techs to Report Earnings Results This Week.
Europe Covid Cases Dampen World Markets
by Mark Vickery
Covid cases here in the U.S. are also troubling: we have a record high new cases per day for three days in a row.
Will AbbVie (ABBV) Q3 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.
Will Pfizer's (PFE) Oncology Drugs Drive Its Q3 Earnings?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the third quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug
by Zacks Equity Research
Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.
Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
Merck (MRK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
Merck (MRK) Stock Moves -1.45%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.67, moving -1.45% from the previous trading session.